Here are the 10-K annual reports from Larimar Therapeutics, Inc. (LRMR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LRMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LRMR filings page.
Larimar Therapeutics is a clinical-stage biotech focused on rare diseases, led by nomlabofusp for Friedreich’s ataxia (FA). Nomlabofusp uses a cell-penetrating peptide platform to deliver frataxin into mitochondria, aiming to correct the underlying protein deficiency in FA rather than just symptoms.
The company has completed four clinical studies and is running an open-label trial with daily 50 mg dosing, where roughly 8,000 doses have been given. Nomlabofusp holds multiple U.S. and European regulatory designations, participates in FDA’s START pilot, and has Breakthrough Therapy status. Larimar targets a June 2026 BLA submission for accelerated approval using skin frataxin as a surrogate endpoint, alongside a global Phase 3 confirmatory study.
Safety is a key focus: injection site reactions are the most common adverse events, and anaphylaxis has been identified as a likely drug-related reaction, leading to protocol changes including premedication and modified initial dosing. As of December 31, 2025, cash, cash equivalents and marketable securities were $136.9 million, and a February 2026 equity offering added $107.6 million in net proceeds, which together are expected to fund operations into the second quarter of 2027.